Trial record 1 of 1 for:
A8081005
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This study is currently recruiting participants.
Verified May 2013 by Pfizer
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00932451
First received: June 30, 2009
Last updated: May 3, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.
| Condition | Intervention | Phase |
|---|---|---|
|
Carcinoma, Non-Small-Cell Lung |
Drug: PF-02341066 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Objective Response Rate [ Time Frame: 30 months ] [ Designated as safety issue: No ]
- Type, incidence, severity, seriousness and relationship to study medication of adverse events and laboratory test abnormalities [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Duration of Response [ Time Frame: 30 months ] [ Designated as safety issue: No ]
- Disease Control Rate [ Time Frame: 30 months ] [ Designated as safety issue: No ]
- Overall Survival [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
- Patient reported symptoms of lung cancer and health-related quality of life [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
- Plasma concentrations of PF-02341066 [ Time Frame: 30 months ] [ Designated as safety issue: No ]
- Types of EML4-ALK fusion variants and ALK gene expression [ Time Frame: 30 months ] [ Designated as safety issue: No ]
- Protein expression of identified biomarkers in serial tumor samples (when available) [ Time Frame: 30 months ] [ Designated as safety issue: No ]
- Progression Free Survival [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
- Time to Tumor Response [ Time Frame: 30 months ] [ Designated as safety issue: No ]
- QTc [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
- genotypes of alleles possibly associated with adverse hepatic or renal drug reactions [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 1100 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: PF-0231066 |
Drug: PF-02341066
PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- histologically or cytologically proven diagnosis of non-small cell lung cancer
- positive for the ALK fusion gene (test provided by either a central laboratory. Local laboratory may be used for certain cases)
- may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and discontinued treatment due to Response Evaluation Criterion in Solid Tumors (RECIST)-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without RECIST-defined progression.
- Tumors can be measurable or non measurable
Exclusion Criteria:
- prior treatment with PF-02341066
- received no prior systemic treatment, chemotherapy or EGFR tyrosine kinase inhibitor, for advanced non-small cell lung cancer
- current enrollment in another therapeutic clinical trial
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00932451
Hide Study Locations
Contacts
| Contact: Pfizer CT.gov Call Center | 1-800-718-1021 | |
| Contact: Pfizer Oncology Clinical Trial Information Service | 1-877-369-9753 | PfizerCancerTrials@emergingmed.com |
Hide Study LocationsLocations
| United States, Alabama | |
| Pfizer Investigational Site | Active, not recruiting |
| Birmingham, Alabama, United States, 35233 | |
| Pfizer Investigational Site | Active, not recruiting |
| Birmingham, Alabama, United States, 35294 | |
| United States, Arkansas | |
| Pfizer Investigational Site | Active, not recruiting |
| Little Rock, Arkansas, United States, 72205 | |
| United States, California | |
| Pfizer Investigational Site | Active, not recruiting |
| Bakersfield, California, United States, 93309 | |
| Pfizer Investigational Site | Active, not recruiting |
| Beverly Hills, California, United States, 90211-1850 | |
| Pfizer Investigational Site | Active, not recruiting |
| Beverly Hills, California, United States, 90211 | |
| Pfizer Investigational Site | Active, not recruiting |
| La Jolla, California, United States, 92093-0698 | |
| Pfizer Investigational Site | Active, not recruiting |
| La Jolla, California, United States, 92307 | |
| Pfizer Investigational Site | Active, not recruiting |
| Los Angeles, California, United States, 90095 | |
| Pfizer Investigational Site | Active, not recruiting |
| Los Angeles, California, United States, 90095-6984 | |
| Pfizer Investigational Site | Active, not recruiting |
| Orange, California, United States, 92868-3298 | |
| Pfizer Investigational Site | Active, not recruiting |
| Palo Alto, California, United States, 94305 | |
| Pfizer Investigational Site | Active, not recruiting |
| Sacramento, California, United States, 95817 | |
| Pfizer Investigational Site | Active, not recruiting |
| San Diego, California, United States, 92103 | |
| Pfizer Investigational Site | Active, not recruiting |
| Santa Monica, California, United States, 90404 | |
| Pfizer Investigational Site | Terminated |
| Santa Rosa, California, United States, 95403 | |
| United States, Colorado | |
| Pfizer Investigational Site | Active, not recruiting |
| Aurora, Colorado, United States, 80045 | |
| Pfizer Investigational Site | Active, not recruiting |
| Denver, Colorado, United States, 80205 | |
| Pfizer Investigational Site | Active, not recruiting |
| Lafayette, Colorado, United States, 80026 | |
| United States, Connecticut | |
| Pfizer Investigational Site | Active, not recruiting |
| New Haven, Connecticut, United States, 06520 | |
| Pfizer Investigational Site | Active, not recruiting |
| New Haven, Connecticut, United States, 06519 | |
| Pfizer Investigational Site | Active, not recruiting |
| New Haven, Connecticut, United States, 06510 | |
| United States, Florida | |
| Pfizer Investigational Site | Terminated |
| Fort Lauderdale, Florida, United States, 33308 | |
| Pfizer Investigational Site | Active, not recruiting |
| Hollywood, Florida, United States, 33021 | |
| Pfizer Investigational Site | Active, not recruiting |
| Lake Worth, Florida, United States, 33461 | |
| Pfizer Investigational Site | Active, not recruiting |
| Pembroke Pines, Florida, United States, 33028 | |
| Pfizer Investigational Site | Active, not recruiting |
| Tampa, Florida, United States, 33612 | |
| United States, Georgia | |
| Pfizer Investigational Site | Active, not recruiting |
| Atlanta, Georgia, United States, 30341 | |
| Pfizer Investigational Site | Active, not recruiting |
| Atlanta, Georgia, United States, 30322 | |
| Pfizer Investigational Site | Active, not recruiting |
| Atlanta, Georgia, United States, 30308 | |
| Pfizer Investigational Site | Terminated |
| Augusta, Georgia, United States, 30912 | |
| Pfizer Investigational Site | Active, not recruiting |
| Decatur, Georgia, United States, 30033 | |
| Pfizer Investigational Site | Active, not recruiting |
| Macon, Georgia, United States, 31217 | |
| Pfizer Investigational Site | Active, not recruiting |
| Marietta, Georgia, United States, 30060 | |
| Pfizer Investigational Site | Active, not recruiting |
| Sandy Springs, Georgia, United States, 30342 | |
| United States, Hawaii | |
| Pfizer Investigational Site | Terminated |
| Honolulu, Hawaii, United States, 96813 | |
| Pfizer Investigational Site | Terminated |
| Honolulu, Hawaii, United States, 96817 | |
| United States, Illinois | |
| Pfizer Investigational Site | Active, not recruiting |
| Chicago, Illinois, United States, 60612 | |
| Pfizer Investigational Site | Active, not recruiting |
| Chicago, Illinois, United States, 60637 | |
| Pfizer Investigational Site | Terminated |
| Harvey, Illinois, United States, 60426 | |
| Pfizer Investigational Site | Terminated |
| Tinley Park, Illinois, United States, 60477 | |
| United States, Indiana | |
| Pfizer Investigational Site | Recruiting |
| Indianapolis, Indiana, United States, 46202 | |
| Pfizer Investigational Site | Recruiting |
| Indianopolis, Indiana, United States, 46290 | |
| Pfizer Investigational Site | Terminated |
| Munster, Indiana, United States, 46321 | |
| United States, Maryland | |
| Pfizer Investigational Site | Active, not recruiting |
| Baltimore, Maryland, United States, 21231 | |
| Pfizer Investigational Site | Active, not recruiting |
| Bethesda, Maryland, United States, 20892 | |
| United States, Massachusetts | |
| Pfizer Investigational Site | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Pfizer Investigational Site | Recruiting |
| Boston, Massachusetts, United States, 02115 | |
| Pfizer Investigational Site | Recruiting |
| Boston, Massachusetts, United States, 02215 | |
| United States, Michigan | |
| Pfizer Investigational Site | Recruiting |
| Detroit, Michigan, United States, 48201 | |
| Pfizer Investigational Site | Recruiting |
| Farmington Hills, Michigan, United States, 48334 | |
| United States, Missouri | |
| Pfizer Investigational Site | Active, not recruiting |
| Creve Coeur, Missouri, United States, 63141 | |
| Pfizer Investigational Site | Active, not recruiting |
| St. Louis, Missouri, United States, 63110-1094 | |
| Pfizer Investigational Site | Active, not recruiting |
| St. Louis, Missouri, United States, 63110 | |
| Pfizer Investigational Site | Active, not recruiting |
| St. Peters, Missouri, United States, 63376 | |
| United States, Nebraska | |
| Pfizer Investigational Site | Active, not recruiting |
| Omaha, Nebraska, United States, 68198-7680 | |
| United States, New Hampshire | |
| Pfizer Investigational Site | Active, not recruiting |
| Lebanon, New Hampshire, United States, 03756-0001 | |
| United States, New Mexico | |
| Pfizer Investigational Site | Active, not recruiting |
| Albuquerque, New Mexico, United States, 87131 | |
| Pfizer Investigational Site | Active, not recruiting |
| Albuquerque, New Mexico, United States, 87106 | |
| United States, New York | |
| Pfizer Investigational Site | Active, not recruiting |
| Lake Success, New York, United States, 11042 | |
| Pfizer Investigational Site | Active, not recruiting |
| Manhasset, New York, United States, 11030 | |
| Pfizer Investigational Site | Active, not recruiting |
| New Hyde Park, New York, United States, 11040 | |
| Pfizer Investigational Site | Active, not recruiting |
| New York, New York, United States, 10065 | |
| Pfizer Investigational Site | Active, not recruiting |
| New York, New York, United States, 10032 | |
| Pfizer Investigational Site | Active, not recruiting |
| Oneida, New York, United States, 13421 | |
| Pfizer Investigational Site | Active, not recruiting |
| Oswego, New York, United States, 13126 | |
| Pfizer Investigational Site | Active, not recruiting |
| Syracuse, New York, United States, 13210-2306 | |
| Pfizer Investigational Site | Active, not recruiting |
| Syracuse, New York, United States, 13210 | |
| United States, North Carolina | |
| Pfizer Investigational Site | Active, not recruiting |
| Chapel Hill, North Carolina, United States, 27514 | |
| Pfizer Investigational Site | Active, not recruiting |
| Chapel Hill, North Carolina, United States, 27599-7600 | |
| Pfizer Investigational Site | Active, not recruiting |
| Charlotte, North Carolina, United States, 28204 | |
| Pfizer Investigational Site | Active, not recruiting |
| Huntersville, North Carolina, United States, 28078 | |
| Pfizer Investigational Site | Active, not recruiting |
| Matthews, North Carolina, United States, 28105 | |
| United States, Ohio | |
| Pfizer Investigational Site | Recruiting |
| Cleveland, Ohio, United States, 44195 | |
| Pfizer Investigational Site | Active, not recruiting |
| Columbus, Ohio, United States, 43205 | |
| Pfizer Investigational Site | Active, not recruiting |
| Columbus, Ohio, United States, 43210 | |
| Pfizer Investigational Site | Active, not recruiting |
| Columbus, Ohio, United States, 43221 | |
| United States, Oregon | |
| Pfizer Investigational Site | Active, not recruiting |
| Beaverton, Oregon, United States, 97006 | |
| Pfizer Investigational Site | Active, not recruiting |
| Gresham, Oregon, United States, 97030 | |
| Pfizer Investigational Site | Active, not recruiting |
| Portland, Oregon, United States, 97216 | |
| Pfizer Investigational Site | Active, not recruiting |
| Portland, Oregon, United States, 97239 | |
| Pfizer Investigational Site | Active, not recruiting |
| Portland, Oregon, United States, 97210 | |
| Pfizer Investigational Site | Active, not recruiting |
| Tualatin, Oregon, United States, 97062 | |
| United States, Pennsylvania | |
| Pfizer Investigational Site | Terminated |
| Hershey, Pennsylvania, United States, 17033-0850 | |
| Pfizer Investigational Site | Active, not recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Pfizer Investigational Site | Active, not recruiting |
| Philadelphia, Pennsylvania, United States, 19111 | |
| Pfizer Investigational Site | Active, not recruiting |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| United States, Rhode Island | |
| Pfizer Investigational Site | Terminated |
| East Providence, Rhode Island, United States, 02915 | |
| Pfizer Investigational Site | Terminated |
| East Providence, Rhode Island, United States, 02914 | |
| United States, South Carolina | |
| Pfizer Investigational Site | Active, not recruiting |
| Charleston, South Carolina, United States, 29425 | |
| United States, Tennessee | |
| Pfizer Investigational Site | Active, not recruiting |
| Dickson, Tennessee, United States, 37055 | |
| Pfizer Investigational Site | Active, not recruiting |
| Franklin, Tennessee, United States, 37067 | |
| Pfizer Investigational Site | Active, not recruiting |
| Gallatin, Tennessee, United States, 37066 | |
| Pfizer Investigational Site | Active, not recruiting |
| Hermitage, Tennessee, United States, 37076 | |
| Pfizer Investigational Site | Active, not recruiting |
| Lebanon, Tennessee, United States, 37087 | |
| Pfizer Investigational Site | Active, not recruiting |
| Murfreesboro, Tennessee, United States, 37130 | |
| Pfizer Investigational Site | Active, not recruiting |
| Nashville, Tennessee, United States, 37232-5536 | |
| Pfizer Investigational Site | Active, not recruiting |
| Nashville, Tennessee, United States, 37211 | |
| Pfizer Investigational Site | Active, not recruiting |
| Nashville, Tennessee, United States, 37205 | |
| Pfizer Investigational Site | Active, not recruiting |
| Nashville, Tennessee, United States, 37203 | |
| Pfizer Investigational Site | Active, not recruiting |
| Nashville, Tennessee, United States, 37207 | |
| Pfizer Investigational Site | Active, not recruiting |
| Nashville, Tennessee, United States, 37232-7610 | |
| Pfizer Investigational Site | Active, not recruiting |
| Smyrna, Tennessee, United States, 37167 | |
| United States, Texas | |
| Pfizer Investigational Site | Active, not recruiting |
| Dallas, Texas, United States, 75232 | |
| Pfizer Investigational Site | Active, not recruiting |
| Dallas, Texas, United States, 75235 | |
| Pfizer Investigational Site | Active, not recruiting |
| Dallas, Texas, United States, 75390 | |
| Pfizer Investigational Site | Active, not recruiting |
| Houston, Texas, United States, 77030 | |
| United States, Washington | |
| Pfizer Investigational Site | Recruiting |
| Seattle, Washington, United States, 98122 | |
| Pfizer Investigational Site | Recruiting |
| Seattle, Washington, United States, 98195 | |
| Pfizer Investigational Site | Recruiting |
| Seattle, Washington, United States, 98109 | |
| Pfizer Investigational Site | Recruiting |
| Seattle, Washington, United States, 98104 | |
| Australia, New South Wales | |
| Pfizer Investigational Site | Active, not recruiting |
| Camperdown, New South Wales, Australia, 2050 | |
| Australia, South Australia | |
| Pfizer Investigational Site | Completed |
| Adelaide, South Australia, Australia, 5000 | |
| Australia, Victoria | |
| Pfizer Investigational Site | Recruiting |
| East Melbourne, Victoria, Australia, 3002 | |
| Australia, Western Australia | |
| Pfizer Investigational Site | Terminated |
| Nedlands, Western Australia, Australia, 6009 | |
| Brazil | |
| Pfizer Investigational Site | Active, not recruiting |
| Salvador, BA, Brazil, 40170-110 | |
| Pfizer Investigational Site | Active, not recruiting |
| Rio de Janeiro, RJ, Brazil, 20231 -050 | |
| Pfizer Investigational Site | Terminated |
| Ijui, RS, Brazil, 98700-000 | |
| Pfizer Investigational Site | Active, not recruiting |
| Porto Alegre, RS, Brazil, 90050-170 | |
| Pfizer Investigational Site | Active, not recruiting |
| Porto Alegre, RS, Brazil, 90610-000 | |
| Pfizer Investigational Site | Terminated |
| Jau, Sao Paulo, Brazil, 17210-120 | |
| Pfizer Investigational Site | Completed |
| Barretos, SP, Brazil, 14784-400 | |
| Pfizer Investigational Site | Terminated |
| Sao Paulo, SP, Brazil, 01509-900 | |
| Pfizer Investigational Site | Completed |
| Sao Paulo, SP, Brazil, 01246-000 | |
| Bulgaria | |
| Pfizer Investigational Site | Active, not recruiting |
| Sofia, Bulgaria, 1606 | |
| Pfizer Investigational Site | Active, not recruiting |
| Sofia, Bulgaria, 1303 | |
| Pfizer Investigational Site | Terminated |
| Sofia, Bulgaria, 1756 | |
| Pfizer Investigational Site | Terminated |
| Varna, Bulgaria, 9002 | |
| Canada, Alberta | |
| Pfizer Investigational Site | Terminated |
| Calgary, Alberta, Canada, T2V 2C4 | |
| Pfizer Investigational Site | Terminated |
| Calgary, Alberta, Canada, T2S 3C3 | |
| Pfizer Investigational Site | Terminated |
| Calgary, Alberta, Canada, T2N 4N2 | |
| Pfizer Investigational Site | Completed |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Canada, New Brunswick | |
| Pfizer Investigational Site | Terminated |
| Moncton, New Brunswick, Canada, E1C 8X3 | |
| Pfizer Investigational Site | Terminated |
| Moncton, New Brunswick, Canada, E1C 2Z3 | |
| Canada, Ontario | |
| Pfizer Investigational Site | Active, not recruiting |
| Oshawa, Ontario, Canada, L1J 8N8 | |
| Pfizer Investigational Site | Active, not recruiting |
| Oshawa, Ontario, Canada, L1G 2B9 | |
| Pfizer Investigational Site | Active, not recruiting |
| Ottawa, Ontario, Canada, K1H 8L6 | |
| Canada, Quebec | |
| Pfizer Investigational Site | Terminated |
| Montreal, Quebec, Canada, H3A 1A1 | |
| Pfizer Investigational Site | Terminated |
| Montreal, Quebec, Canada, H3G 1A4 | |
| Pfizer Investigational Site | Terminated |
| Montreal, Quebec, Canada, H2L 4M1 | |
| Pfizer Investigational Site | Terminated |
| Montreal, Quebec, Canada, H3T 1E2 | |
| Pfizer Investigational Site | Terminated |
| Montreal, Quebec, Canada, H3T 1M5 | |
| China, Jiangsu | |
| Pfizer Investigational Site | Active, not recruiting |
| Nanjing, Jiangsu, China, 210002 | |
| China | |
| Pfizer Investigational Site | Active, not recruiting |
| Beijing, China, 100071 | |
| Pfizer Investigational Site | Recruiting |
| Beijing, China, 100021 | |
| Pfizer Investigational Site | Active, not recruiting |
| Guangzhou, China, 510060 | |
| Pfizer Investigational Site | Active, not recruiting |
| Guangzhou, China, 510080 | |
| Pfizer Investigational Site | Recruiting |
| Shanghai, China, 200433 | |
| Pfizer Investigational Site | Active, not recruiting |
| Shanghai, China, 200032 | |
| Pfizer Investigational Site | Active, not recruiting |
| Shanghai, China, 200030 | |
| France | |
| Pfizer Investigational Site | Active, not recruiting |
| Argenteuil Cedex, France, 95107 | |
| Pfizer Investigational Site | Active, not recruiting |
| Boulogne-Billancourt, France, 92100 | |
| Pfizer Investigational Site | Active, not recruiting |
| Caen Cedex 05, France, 14076 | |
| Pfizer Investigational Site | Active, not recruiting |
| Creil, France, 94000 | |
| Pfizer Investigational Site | Active, not recruiting |
| Dijon, France, 21079 | |
| Pfizer Investigational Site | Active, not recruiting |
| Grenoble Cedex 09, France, 38043 | |
| Pfizer Investigational Site | Active, not recruiting |
| Longjumeau Cedex 01, France, 91161 | |
| Pfizer Investigational Site | Active, not recruiting |
| Marseille Cedex 20, France, 13915 | |
| Pfizer Investigational Site | Active, not recruiting |
| NICE Cedex 2, France, 06189 | |
| Pfizer Investigational Site | Active, not recruiting |
| Paris, France, 75005 | |
| Pfizer Investigational Site | Active, not recruiting |
| Paris Cedex 12, France, 75571 | |
| Pfizer Investigational Site | Completed |
| Paris Cedex 14, France, 75679 | |
| Pfizer Investigational Site | Active, not recruiting |
| Paris cedex 20, France, 75970 | |
| Pfizer Investigational Site | Active, not recruiting |
| St Herblain Cedex, France, 44805 | |
| Pfizer Investigational Site | Active, not recruiting |
| Suresnes, France, 92150 | |
| Pfizer Investigational Site | Active, not recruiting |
| Villejuif, France, 94805 | |
| Germany | |
| Pfizer Investigational Site | Recruiting |
| Dresden, Germany, 01307 | |
| Pfizer Investigational Site | Recruiting |
| Essen, Germany, 45122 | |
| Pfizer Investigational Site | Active, not recruiting |
| Grosshansdorf, Germany, 22927 | |
| Pfizer Investigational Site | Active, not recruiting |
| Hamburg, Germany, 22527 | |
| Pfizer Investigational Site | Recruiting |
| Heidelberg, Germany, 69126 | |
| Pfizer Investigational Site | Recruiting |
| Karlsruhe, Germany, 76137 | |
| Pfizer Investigational Site | Active, not recruiting |
| Koeln, Germany, 50937 | |
| Pfizer Investigational Site | Recruiting |
| Muenchen, Germany, 80336 | |
| Pfizer Investigational Site | Active, not recruiting |
| Oldenburg, Germany, 26121 | |
| Pfizer Investigational Site | Recruiting |
| Wiesbaden, Germany, 65199 | |
| Greece | |
| Pfizer Investigational Site | Active, not recruiting |
| Heraklion, Crete, Greece, 71110 | |
| Pfizer Investigational Site | Terminated |
| Exohi, Thessaloniki, Greece, 57010 | |
| Pfizer Investigational Site | Active, not recruiting |
| Athens, Greece, 11527 | |
| Hong Kong | |
| Pfizer Investigational Site | Active, not recruiting |
| Pokfulam, Hong Kong | |
| Pfizer Investigational Site | Active, not recruiting |
| Shatin, New Territories, Hong Kong | |
| Pfizer Investigational Site | Active, not recruiting |
| Tuen Mun, New Territories, Hong Kong | |
| Hungary | |
| Pfizer Investigational Site | Terminated |
| Budapest, Hungary, 1125 | |
| Pfizer Investigational Site | Completed |
| Budapest, Hungary, 1121 | |
| Pfizer Investigational Site | Completed |
| Debrecen, Hungary, 4032 | |
| Pfizer Investigational Site | Terminated |
| Farkasgyepu, Hungary, 8582 | |
| Pfizer Investigational Site | Terminated |
| Szekesfehervar, Hungary, 8000 | |
| Pfizer Investigational Site | Terminated |
| Torokbalint, Hungary, 2045 | |
| Ireland | |
| Pfizer Investigational Site | Active, not recruiting |
| Dublin 8, Ireland | |
| Pfizer Investigational Site | Terminated |
| Galway, Ireland | |
| Italy | |
| Pfizer Investigational Site | Recruiting |
| Avellino, Italy, 83100 | |
| Pfizer Investigational Site | Active, not recruiting |
| Firenze, Italy, 50139 | |
| Pfizer Investigational Site | Completed |
| Genova, Italy, 16132 | |
| Pfizer Investigational Site | Completed |
| Lido di Camaiore (LU), Italy, 55043 | |
| Pfizer Investigational Site | Recruiting |
| Lucca, Italy, 55100 | |
| Pfizer Investigational Site | Recruiting |
| Milano, Italy, 20162 | |
| Pfizer Investigational Site | Recruiting |
| Milano, Italy, 20132 | |
| Pfizer Investigational Site | Recruiting |
| Milano, Italy, 20141 | |
| Pfizer Investigational Site | Recruiting |
| Monza, Italy, 20052 | |
| Pfizer Investigational Site | Recruiting |
| Orbassano (TO), Italy, 10043 | |
| Pfizer Investigational Site | Active, not recruiting |
| Perugia, Italy, 06132 | |
| Pfizer Investigational Site | Recruiting |
| Roma, Italy, 00152 | |
| Pfizer Investigational Site | Completed |
| Torino, Italy, 10126 | |
| Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Nagoya, Aichi, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Kashiwa, Chiba, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Sapporo, Hokkaido, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Akashi, Hyogo, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Okayama-city, Okayama, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Osakasayama-shi, Osaka, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Sunto-gun, Shizuoka, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Chuo-ku, Tokyo, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Fukuoka, Japan | |
| Pfizer Investigational Site | Active, not recruiting |
| Tokyo, Japan | |
| Korea, Republic of | |
| Pfizer Investigational Site | Active, not recruiting |
| Gyeonggi-do, Korea, Republic of, 410-769 | |
| Pfizer Investigational Site | Recruiting |
| Seoul, Korea, Republic of, 110-744 | |
| Pfizer Investigational Site | Recruiting |
| Seoul, Korea, Republic of, 135-710 | |
| Netherlands | |
| Pfizer Investigational Site | Active, not recruiting |
| Groningen, Netherlands, 9713 GZ | |
| Poland | |
| Pfizer Investigational Site | Active, not recruiting |
| Gdansk, Poland, 80-952 | |
| Pfizer Investigational Site | Active, not recruiting |
| Olsztyn, Poland, 10-357 | |
| Pfizer Investigational Site | Terminated |
| Poznan, Poland, 60-569 | |
| Russian Federation | |
| Pfizer Investigational Site | Terminated |
| Kazan, Russian Federation, 420029 | |
| Pfizer Investigational Site | Terminated |
| Moscow, Russian Federation, 115478 | |
| Pfizer Investigational Site | Active, not recruiting |
| Saint-Petersburg, Russian Federation, 198255 | |
| Pfizer Investigational Site | Active, not recruiting |
| Saint-Petersburg, Russian Federation, 197089 | |
| Pfizer Investigational Site | Active, not recruiting |
| Saint-Petersburg, Russian Federation, 197022 | |
| Pfizer Investigational Site | Active, not recruiting |
| St. Petersburg, Russian Federation, 197022 | |
| Spain | |
| Pfizer Investigational Site | Active, not recruiting |
| Oviedo, Asturias, Spain, 33006 | |
| Pfizer Investigational Site | Active, not recruiting |
| Badalona, Barcelona, Spain, 08916 | |
| Pfizer Investigational Site | Active, not recruiting |
| Lahospitalet de Llobregat, Barcelona, Spain, 08907 | |
| Pfizer Investigational Site | Active, not recruiting |
| Sabadell, Barcelona, Spain, 08208 | |
| Pfizer Investigational Site | Active, not recruiting |
| Pamplona, Navarra, Spain, 31008 | |
| Pfizer Investigational Site | Active, not recruiting |
| A Coru, Spain, 15006 | |
| Pfizer Investigational Site | Active, not recruiting |
| Barcelona, Spain, 08035 | |
| Pfizer Investigational Site | Active, not recruiting |
| Barcelona, Spain, 08003 | |
| Pfizer Investigational Site | Recruiting |
| Madrid, Spain, 28046 | |
| Pfizer Investigational Site | Terminated |
| Santander, Spain, 39008 | |
| Pfizer Investigational Site | Terminated |
| Sevilla, Spain, 41013 | |
| Sweden | |
| Pfizer Investigational Site | Recruiting |
| Stockholm, Sweden, 171 76 | |
| Taiwan | |
| Pfizer Investigational Site | Active, not recruiting |
| Tainan, Taiwan, 704 | |
| Pfizer Investigational Site | Active, not recruiting |
| Taipei, Taiwan, 100 | |
| Pfizer Investigational Site | Active, not recruiting |
| Taipei, Taiwan, 112 | |
| United Kingdom | |
| Pfizer Investigational Site | Active, not recruiting |
| Headington, Oxford, United Kingdom, OX3 7LJ | |
| Pfizer Investigational Site | Recruiting |
| Sutton, Surrey, United Kingdom, SM2 5PT | |
| Pfizer Investigational Site | Active, not recruiting |
| Eastleigh, United Kingdom, SO53 2DW | |
| Pfizer Investigational Site | Active, not recruiting |
| London, United Kingdom, NW3 2QG | |
| Pfizer Investigational Site | Recruiting |
| London, United Kingdom, SW3 6JJ | |
| Pfizer Investigational Site | Completed |
| London, United Kingdom, SE1 9RT | |
| Pfizer Investigational Site | Recruiting |
| Manchester, United Kingdom, M20 4BX | |
| Pfizer Investigational Site | Active, not recruiting |
| Southampton, United Kingdom, SO16 6YD | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided by Pfizer
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00932451 History of Changes |
| Other Study ID Numbers: | A8081005 |
| Study First Received: | June 30, 2009 |
| Last Updated: | May 3, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Pfizer:
|
Lung Neoplasms ALK gene Crizotinib |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Non-Small-Cell Lung Lung Neoplasms Lymphoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms |
Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013